Cited 0 times in Scipus Cited Count

S78: Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study

DC Field Value Language
dc.contributor.authorPavord, I-
dc.contributor.authorPapi, A-
dc.contributor.authorWenzel, S-
dc.contributor.authorPark, HS-
dc.contributor.authorRice, M-
dc.contributor.authorStaudinger, H-
dc.contributor.authorMaroni, J-
dc.contributor.authorRowe, P-
dc.contributor.authorRout, R-
dc.contributor.authorAmin, N-
dc.contributor.authorAkinlade, B-
dc.contributor.authorGraham, NMH-
dc.contributor.authorTeper, A-
dc.date.accessioned2019-12-10T06:53:42Z-
dc.date.available2019-12-10T06:53:42Z-
dc.date.issued2018-
dc.identifier.issn0040-6376-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/17804-
dc.language.isoen-
dc.titleS78: Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study-
dc.typeArticle-
dc.contributor.affiliatedAuthor박, 해심-
dc.type.localJournal Papers-
dc.identifier.doi10.1136/thorax-2018-212555.84-
dc.citation.titleThorax-
dc.citation.volume73-
dc.citation.numberS4-
dc.citation.date2018-
dc.citation.startPageA48-
dc.citation.endPageA48-
dc.identifier.bibliographicCitationThorax, 73(S4). : A48-A48, 2018-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1468-3296-
dc.relation.journalidJ000406376-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Allergy
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse